Swiss National Bank Vaxart, Inc. Transaction History

Swiss National Bank

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 09, 2022	BUY	$4.29 - $6.64 $114,114 - $176,624	26,600 Added 9.85%	296,700 $1.5 Million
Q3 2021 Nov 08, 2021	BUY	$6.67 - $9.8 $70,035 - $102,900	10,500 Added 4.04%	270,100 $2.15 Million
Q2 2021 Aug 06, 2021	BUY	$5.06 - $10.78 $48,069 - $102,410	9,500 Added 3.8%	259,600 $1.94 Million
Q1 2021 May 07, 2021	BUY	$5.64 - $23.33 $14,664 - $60,657	2,600 Added 1.05%	250,100 $1.51 Million
Q4 2020 Feb 05, 2021	BUY	$3.5 - $7.98 $866,250 - $1.98 Million	247,500 New	247,500 $1.41 Million

110

37.6M

188K

180K

Ticker VXRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 126,506,000
Market Cap $73.4M
Description
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.